What's hot

View all perspectives
      Sarcoid - diagnosis of probability!
      Biopsy not required! Can be bx-supported, not confirmed!

      Calcium in Sarcoid
      10-20%

      Eric Dein ericdeinmd

      9 months 4 weeks ago
      Sarcoid - diagnosis of probability! Biopsy not required! Can be bx-supported, not confirmed! Calcium in Sarcoid 10-20% hypercalcemic 30-50% hypercalcuria Sc: polyuria, dehydration, confusion, depression, fatigue, n/v, anorexia, abd pain, hematuria @RheumNow #ACR24 Rev Course https://t.co/B1srD3saij
      Upadacitinib (UPA), a new oral treatment option for GCA? Dr. Peter Merkel discusses SELECT-GCA.
      UPA15 + 26-week GC taper

      Jiha Lee JihaRheum

      9 months 4 weeks ago
      Upadacitinib (UPA), a new oral treatment option for GCA? Dr. Peter Merkel discusses SELECT-GCA. UPA15 + 26-week GC taper >> PBO with a 52-week GC taper for GCA remission. #ACR24 #ACRBest @RheumNow ABST#0770 https://t.co/UbQLVA8X7r
      Where do SGLT2i have proven benefits for CVD?
      👉 Diabetes w/high CV risk
      👉Heart failure (all EF)
      👉CKD
      Dr Weber

      TheDaoIndex KDAO2011

      9 months 4 weeks ago
      Where do SGLT2i have proven benefits for CVD? 👉 Diabetes w/high CV risk 👉Heart failure (all EF) 👉CKD Dr Weber @rheumnow #ACR24 https://t.co/vFYddrLP1Y
      It's been a wild ride over the last 20 years of RA b/tsDMARDs, and fascinating to see how our prescribing habits have ch

      David Liew drdavidliew

      9 months 4 weeks ago
      It's been a wild ride over the last 20 years of RA b/tsDMARDs, and fascinating to see how our prescribing habits have changed over that time. MarketScan data tell a story of fashion and fame. What will the next 20 years be like? #ACR24 ABST0509 @jeffsparks @RheumNow https://t.co/wCcWgkHrvc
      Major update in tx for GCA beyond Toci

      SELECT-GCA showed upadacitinib 15mg daily achieving higher rates of remission wi

      Brian Jaros, MD Dr_Brian_MD

      9 months 4 weeks ago
      Major update in tx for GCA beyond Toci SELECT-GCA showed upadacitinib 15mg daily achieving higher rates of remission with SHORTER (26wk) steroid use compared to placebo (52wk) No significant adverse safety signal w JAKi including MACE/malignancy @RheumNow #ACR24 Abstract 0770 https://t.co/45D0Txed2N
      TNFi cycling vs. switching to IL-17Ai?
      Dr @AlexisOgdie et al from CorEvitas registry:
      PsA & axSpA cohort - switche

      sheila RHEUMarampa

      9 months 4 weeks ago
      TNFi cycling vs. switching to IL-17Ai? Dr @AlexisOgdie et al from CorEvitas registry: PsA & axSpA cohort - switchers (TNFi to IL17i) had greater improvements in cDAPSA & BASDAI vs. cyclers (2nd TNF) Not stat significant but offers alternative Tx options @RheumNow #ACR24 abs585 https://t.co/8m347BRM75
      SELECT trial noted reduction in CV death, MI and stroke in obese pts without diabetes (other benefits: reduction in wais

      TheDaoIndex KDAO2011

      9 months 4 weeks ago
      SELECT trial noted reduction in CV death, MI and stroke in obese pts without diabetes (other benefits: reduction in waist circumference, BP, lipids) @rheumnow # ACR24 https://t.co/GPK4Vg5bOt
      #ACR24 Ab#0771
      ARID5B - transcription factor controls pathologic inflammatory fibroblast
      ARID5B: RA risk locus on GWAS,

      Eric Dein ericdeinmd

      9 months 4 weeks ago
      #ACR24 Ab#0771 ARID5B - transcription factor controls pathologic inflammatory fibroblast ARID5B: RA risk locus on GWAS, also link to SLE, Graves Binds to histone editors to epigenetically regulate fibroblast state ARID5B deletion incr inflamm response, overexpr decr @RheumNow https://t.co/ebKnX1uTuO
      GLP1ra is now part of GDMT, including pts without diabetes. The role of rheums in prescribing these remain to be seen. -

      TheDaoIndex KDAO2011

      9 months 4 weeks ago
      GLP1ra is now part of GDMT, including pts without diabetes. The role of rheums in prescribing these remain to be seen. - Dr Weber #ACR24 @rheumnow @ACRheum https://t.co/U9XEhGBXBN
      #0509
      📊 RA DMARD Trends in US (2001-2021)

      🧑‍🤝‍🧑 407,728 DMARD starts in 229,365 patients

      📉 csDMARD

      Caoilfhionn Connolly CaoilfhionnMD

      9 months 4 weeks ago
      #0509 📊 RA DMARD Trends in US (2001-2021) 🧑‍🤝‍🧑 407,728 DMARD starts in 229,365 patients 📉 csDMARD use fell (79.7% → 54.7%) ‼️Methotrexate dropped 29% → 15% 📈 bDMARDs (20.3% →33.1%),tsDMARDs (0.1% → 12.2%) both ⬆️⬆️ 💊Biosimilar uptake low #ACR24 @RheumNow @jeffsparks https://t.co/JepaWj7azY
      Dr. Catherine Bakewell @CatherineB27 shares the preliminary ACR guidelines on ultrasound imaging in psoriatic arthritis

      Antoni Chan MD (Prof) synovialjoints

      9 months 4 weeks ago
      Dr. Catherine Bakewell @CatherineB27 shares the preliminary ACR guidelines on ultrasound imaging in psoriatic arthritis covering 4 domains, detailed PICOs covering the early phase, diagnosis, assessment covering the domains of PsA @RheumNow #ACR24 https://t.co/DoHE1rsSGf
      #0322🔬 Myocarditis in Myositis(IIM)

      📊 26% new IIM pt had myocarditis (ESC,Lake Louise)

      💥 Anti-Ku most common

      Caoilfhionn Connolly CaoilfhionnMD

      9 months 4 weeks ago
      #0322🔬 Myocarditis in Myositis(IIM) 📊 26% new IIM pt had myocarditis (ESC,Lake Louise) 💥 Anti-Ku most common MSA 💥Myocarditis a/w ⬆️heart failure, arrhythmia (43 v 6%;p=0.02) 🎯 Myocarditis🟰poor outcomes 🎯Cardiac MRI🟰earlier detection #ACR24 @RheumNow @JuliePaikMD https://t.co/yz0f2ozFVL
      "If you want an argument, put two rheumatologists in a room and ask them about steroid tapers. Add a third and you'll ha

      Mike Putman EBRheum

      9 months 4 weeks ago
      "If you want an argument, put two rheumatologists in a room and ask them about steroid tapers. Add a third and you'll have a fight" -P. Merkel at UPA plenary session #ACR24 @RheumNow
      How to Master ACR Meetings

      https://t.co/ATbOYbatOy https://t.co/j1oRBbhWY2

      Dr. John Cush RheumNow

      9 months 4 weeks ago
      How to Master ACR Meetings https://t.co/ATbOYbatOy https://t.co/j1oRBbhWY2
      Results from SELECT-GCA➡️UPA 15mg + 26W GC taper demonstrates superior efficacy & reduced GC use vs PBO + 52W

      Mrinalini Dey DrMiniDey

      9 months 4 weeks ago

      Results from SELECT-GCA ➡️UPA 15mg + 26W GC taper demonstrates superior efficacy & reduced GC use vs PBO + 52W GC taper ➡️No new safety signals Is UPA the new kid on the block in #GCA? Ab0770 #ACRBest #ACR24 @RheumNow https://t.co/pHzozYiid5

      How well do you know this week's rheumatology news?
      Take the rheumIQ quiz
      Take the RheumIQ Quiz

      Podcasts

      • ACR24 IL-17 Topic Panel Advancing Care with IL-17 Pathway Insights
      • ACR24 JAK TYK Topic Panel
      • RheumNow Day 1 Recap ACR Convergence 2024 Highlights

      Catch up on Conference Podcasts

      ×